EP3368059A4 - Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1 - Google Patents

Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1 Download PDF

Info

Publication number
EP3368059A4
EP3368059A4 EP16860818.0A EP16860818A EP3368059A4 EP 3368059 A4 EP3368059 A4 EP 3368059A4 EP 16860818 A EP16860818 A EP 16860818A EP 3368059 A4 EP3368059 A4 EP 3368059A4
Authority
EP
European Patent Office
Prior art keywords
fgf
steroid
analogs
treatment
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16860818.0A
Other languages
German (de)
English (en)
Other versions
EP3368059A1 (fr
Inventor
Ronald M. Evans
Michael Downes
Annette Atkins
Ruth T. Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of EP3368059A1 publication Critical patent/EP3368059A1/fr
Publication of EP3368059A4 publication Critical patent/EP3368059A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16860818.0A 2015-10-30 2016-10-27 Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1 Withdrawn EP3368059A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248935P 2015-10-30 2015-10-30
PCT/US2016/059190 WO2017075260A1 (fr) 2015-10-30 2016-10-27 Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1

Publications (2)

Publication Number Publication Date
EP3368059A1 EP3368059A1 (fr) 2018-09-05
EP3368059A4 true EP3368059A4 (fr) 2019-03-27

Family

ID=58631193

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16860818.0A Withdrawn EP3368059A4 (fr) 2015-10-30 2016-10-27 Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1

Country Status (6)

Country Link
US (1) US10695404B2 (fr)
EP (1) EP3368059A4 (fr)
JP (1) JP2018535964A (fr)
AU (1) AU2016344134A1 (fr)
CA (1) CA3002400A1 (fr)
WO (1) WO2017075260A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
WO2017075260A1 (fr) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1
WO2018112200A1 (fr) * 2016-12-15 2018-06-21 Salk Institute For Biological Studies Utilisation du facteur 1 de croissance des fibroblastes (fgf1)-nerf vague ciblant des protéines chimériques pour traiter l'hyperglycémie
AU2019359295A1 (en) * 2018-10-09 2021-06-03 The Board Of Trustees Of The Leland Stanford Junior University Engineered fibroblast growth factor variants as receptor antagonists
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
PL244541B1 (pl) * 2021-05-26 2024-02-05 Celon Pharma Spolka Z Ograniczona Odpowiedzialnoscia Muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1), ich dimery i zastosowania
WO2023019218A1 (fr) * 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Facteurs de croissance des fibroblastes modifiés pour le traitement de maladies fibrotiques
EP4365192A1 (fr) * 2022-11-04 2024-05-08 DSM IP Assets B.V. Production microbienne de facteurs de croissance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130729A2 (fr) * 2010-04-16 2011-10-20 Salk Institute For Biological Studies Procédés de traitement de troubles métaboliques utilisant le fgf
US20150111821A1 (en) * 2013-10-21 2015-04-23 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108459T1 (de) 1986-04-22 1994-07-15 Salk Inst For Biological Studi Antagonisten des fibroblasten-wachstumsfaktors.
US5656458A (en) 1988-11-04 1997-08-12 Chiron Corporation Expression and processing of amino terminus acetylated FGF's in yeast
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
JPH04164096A (ja) 1989-09-29 1992-06-09 Takeda Chem Ind Ltd ａＦＧＦムテイン，ＤＮＡおよびその用途
EP0420222A1 (fr) 1989-09-29 1991-04-03 Takeda Chemical Industries, Ltd. Mutéine du FGF acide, et sa production
US5478804A (en) 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
DE4132005A1 (de) 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
TW275068B (fr) 1993-09-24 1996-05-01 American Cyanamid Co
US5693775A (en) 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
US6326484B1 (en) 1998-05-14 2001-12-04 The Salk Institute For Biological Studies Nucleic acids encoding regulators of FGF-2 transcription (RFT) and variants thereof
US6800286B1 (en) 1998-08-19 2004-10-05 The Regents Of The University Of Colorado Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
WO2002066034A1 (fr) 2001-02-20 2002-08-29 Chugai Seiyaku Kabushiki Kaisha Methode de traitement de maladies metaboliques dans lesquelles sont utilises des inhibiteurs de malonyl-coa decarboxylase
AU2002306921A1 (en) 2001-03-27 2002-10-08 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
WO2003011213A2 (fr) 2001-07-30 2003-02-13 Eli Lilly And Company Methode de traitement du diabete et de l'obesite
US6982170B1 (en) 2001-12-17 2006-01-03 Maine Medical Center Research Institute Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
US8142810B2 (en) 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
NZ537208A (en) 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
NZ543717A (en) 2003-06-05 2008-06-30 Centelion Administration of a plasmid encoding a fibroblast growth factor (FGF), wherein VEGF-A factor expression is not induced in the myocardial or skeletal muscle to treat myocardial or skeletal angiogenic disorders or defects associated with hypercholesterolemia or diabetes
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
JP4477013B2 (ja) 2003-12-10 2010-06-09 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
KR20070006714A (ko) 2003-12-29 2007-01-11 센텔리옹 에스아에스 관상 동맥 또는 말초 허혈 치료
US20090111742A1 (en) 2004-01-26 2009-04-30 Alexei Kharitonenkov Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
CA2557782A1 (fr) 2004-03-17 2005-10-06 Eli Lilly And Company Composes fgf-21 lies au glycol
JP2008506635A (ja) 2004-05-13 2008-03-06 イーライ リリー アンド カンパニー Ｆｇｆ−２１融合タンパク質
ATE513823T1 (de) 2004-08-17 2011-07-15 Simpson Biotech Co Ltd Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung
WO2006028595A2 (fr) 2004-09-02 2006-03-16 Eli Lilly And Company Muteines de facteur de croissance 21 de fibroblaste
EP1789443A1 (fr) 2004-09-02 2007-05-30 Eli Lilly And Company Muteines du facteur de croissance 21 du fibroblaste
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
EP1831371A2 (fr) 2004-12-14 2007-09-12 Eli Lilly And Company Muteines du facteur de croissance fibroblastique 21
US20080261875A1 (en) 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US8168591B2 (en) 2005-10-17 2012-05-01 The Regents Of The University Of California Compositions and methods related to anti-FGF agents
EP2083846B1 (fr) 2006-09-28 2015-07-15 Hepacore Ltd. Variantes fgf n-terminal à sélectivité de récepteur améliorée et ses utilisations
US20100143330A1 (en) 2006-10-16 2010-06-10 Unversidadde Salamanca (O.T.R.I.) Methods of treating disorders associated with fat storage
US7595296B1 (en) 2006-11-09 2009-09-29 Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
WO2008092019A1 (fr) 2007-01-25 2008-07-31 Mayo Foundation For Medical Education And Research Polypeptides du fgf-23
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
EP2139508B1 (fr) 2007-04-02 2013-05-08 Genentech, Inc. Un anticorps anti-klotho beta pour l'utilisation dans le traitement des tumeurs, de cancer ou d'un maladie de prolifération des cellules
JP5187837B2 (ja) 2007-04-06 2013-04-24 独立行政法人産業技術総合研究所 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
US20080260703A1 (en) 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
WO2009048119A1 (fr) 2007-10-12 2009-04-16 National Institute Of Advanced Industrial Science And Technology Composition médicinale contenant une protéine chimère extrêmement fonctionnalisée
EP2234620B1 (fr) 2008-01-03 2016-03-09 Université d'Aix-Marseille Tritherapie utilisable lors du traitement d'un patient infecte par le vih
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US7956033B2 (en) 2008-06-10 2011-06-07 Eu Sol Biotech Co., Ltd. Modified peptide of human acidic fibroblast growth factor
US8062632B2 (en) * 2008-06-23 2011-11-22 National Yang-Ming University Systems and methods for making hepatocytes from extrahepatic somatic stem cells and use thereof
WO2010075037A1 (fr) 2008-12-15 2010-07-01 University Of Rochester Systèmes et procédés pour améliorer l'efficacité de vaccins
JP5599822B2 (ja) 2009-01-23 2014-10-01 ノヴォ ノルディスク アー／エス アルブミンバインダーａ−ｂ−ｃ−ｄ−ｅ−を有するｆｇｆ２１誘導体及びそれらの使用
CA2760674A1 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
PL3248610T3 (pl) 2009-05-05 2024-04-02 Amgen Inc. Mutanty fgf21 i ich zastosowania
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2443145A1 (fr) 2009-06-17 2012-04-25 Amgen, Inc Polypeptides fgf19 chimériques et leurs utilisations
JP6016636B2 (ja) 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2011068893A1 (fr) 2009-12-02 2011-06-09 Amgen Inc. Protéines de liaison qui se lient au fgfr1c humain, au β-klotho humain et à la fois au fgfr1c humain et au β-klotho humain
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
WO2012010553A1 (fr) 2010-07-20 2012-01-26 Novo Nordisk A/S Composés fgf21 n-terminaux modifiés
CN102464712A (zh) 2010-11-11 2012-05-23 重庆富进生物医药有限公司 缺失型人成纤维细胞生长因子21变异体及其偶联物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US8962546B2 (en) 2011-03-01 2015-02-24 Salk Institute For Biological Studies Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor
WO2012140650A2 (fr) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugués de carboxy polysaccharides avec des facteurs de croissance des fibroblastes et variants de ceux-ci
PT2726511T (pt) 2011-07-01 2019-10-14 Ngm Biopharmaceuticals Inc Composições, usos e métodos para o tratamento de distúrbios e doenças metabólicas
AU2012301769B2 (en) 2011-08-31 2016-05-19 Amgen Inc. FGF21 for use in treating type 1 diabetes
US8772460B2 (en) 2011-12-16 2014-07-08 Wisconsin Alumni Research Foundation Thermostable FGF-2 mutant having enhanced stability
WO2013131091A1 (fr) 2012-03-02 2013-09-06 New York University Protéines chimères fgf21 ayant une affinité de liaison augmentée pour le bêta-klotho dans le traitement du diabète de type ii, de l'obésité et des troubles métaboliques apparentés
US20150079003A1 (en) 2012-05-01 2015-03-19 Univeristy of Washington through its Center for Commreicalization Methods and Compositions for Cancer Diagnosis
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014024173A2 (fr) 2012-08-10 2014-02-13 Florida State University Research Foundation Facteur-1 de croissance fibroblastique humain recombinant en tant que nouveau produit thérapeutique pour des maladies ischémiques et procédés associés
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
WO2015061351A1 (fr) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Peptides du facteur de croissance des fibroblastes (fgf) 2/fgf1 chimères, et procédés pour leur utilisation
WO2015061331A1 (fr) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Peptides de facteur de croissance des fibroblastes (fgf) 2/fgf1 chimériques et procédés d'utilisation
JP6560202B2 (ja) 2013-10-28 2019-08-21 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 癌モデル及び関連方法
WO2015149069A1 (fr) 2014-03-28 2015-10-01 New York University Protéines de fusion fgf23
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
JP2017521059A (ja) 2014-06-17 2017-08-03 ザイクローブ セラピューティクス, インク.Xycrobe Therapeutics, Inc. 機械的に位置合わせされた光学的要素及びその製造方法
WO2015198175A1 (fr) 2014-06-27 2015-12-30 Florida State University Research Foundation, Inc. Conception de mutants fgf-1 destinés à éliminer efficacement des résidus cystéine réactifs
EP3227320B1 (fr) 2014-12-03 2019-07-03 Florida State University Research Foundation, Inc. Polypeptides de facteur de croissance des fibroblastes 1 (fgf -1) modifié présentant une affinité de liaison accrue pour l'héparine et procédés associés
WO2016100820A2 (fr) 2014-12-19 2016-06-23 Salk Institute For Biological Studies Troncatures du fgf2 et mutants et utilisations de ceux-ci
EP3285793A4 (fr) 2015-04-20 2018-10-10 Salk Institute for Biological Studies Mutants du facteur de croissance des fibroblastes (fgf) 1 et leurs procédés d'utilisation pour réduire le glucose sanguin
WO2016172153A2 (fr) 2015-04-20 2016-10-27 Salk Institute For Biological Studies Facteur de croissance des fibroblastes (fgf) 1 à mutation dans le domaine de liaison à l'héparine et méthodes d'utilisation pour réduire la glycémie
WO2016172290A1 (fr) 2015-04-21 2016-10-27 Salk Institute For Biological Studies Procédés de traitement de la lipodystrophie à l'aide de composés fgf-1
WO2017075260A1 (fr) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1
WO2018018010A1 (fr) 2016-07-21 2018-01-25 Metacrine, Inc. Mutants de fgf et leurs utilisations
EP3491011A1 (fr) 2016-08-01 2019-06-05 Salk Institute for Biological Studies Protéines du facteur de croissance des fibroblastes (fgf) 1 ayant une capacité de réduction du glucose et une mitogénicité réduite

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130729A2 (fr) * 2010-04-16 2011-10-20 Salk Institute For Biological Studies Procédés de traitement de troubles métaboliques utilisant le fgf
US20150111821A1 (en) * 2013-10-21 2015-04-23 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALEXEI KHARITONENKOV ET AL: "Break on Through to the Other 1", CELL METABOLISM, vol. 20, no. 4, 1 October 2014 (2014-10-01), United States, pages 554 - 555, XP055556121, ISSN: 1550-4131, DOI: 10.1016/j.cmet.2014.09.009 *
JAE MYOUNG SUH ET AL: "Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer", NATURE, vol. 513, no. 7518, 16 July 2014 (2014-07-16), London, pages 436 - 439, XP055335222, ISSN: 0028-0836, DOI: 10.1038/nature13540 *
SACHIKO I. BLABER ET AL: "Accelerated healing in NONcNZO10/LtJ type 2 diabetic mice by FGF-1 : Wound healing in NONcNZO10/LtJ mice", WOUND REPAIR AND REGENERATION., vol. 23, no. 4, 1 July 2015 (2015-07-01), US, pages 538 - 549, XP055556160, ISSN: 1067-1927, DOI: 10.1111/wrr.12305 *
See also references of WO2017075260A1 *

Also Published As

Publication number Publication date
JP2018535964A (ja) 2018-12-06
US10695404B2 (en) 2020-06-30
AU2016344134A1 (en) 2018-05-31
CA3002400A1 (fr) 2017-05-04
WO2017075260A1 (fr) 2017-05-04
US20180228869A1 (en) 2018-08-16
EP3368059A1 (fr) 2018-09-05

Similar Documents

Publication Publication Date Title
EP3368059A4 (fr) Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1
EP3331419A4 (fr) Endoscope avec embout à profil variable
EP3060238A4 (fr) Facteur de croissance de fibroblaste 1 (fgf) muté et méthodes d'utilisation
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
EP3500194A4 (fr) Canule avec caméra montée sur le côté proximal
EP3260139A4 (fr) Insuline ou complexe analogue à l'insuline à action prolongée
EP3248640A4 (fr) Collecteur/injecteur de liquide à usage médical
EP3781147A4 (fr) Insuline sensible au glucose
EP3242605A4 (fr) Traitement angiogénique d'une maladie cardiaque ischémique
EP3297653A4 (fr) Traitement de l'hypoglycémie post-bariatrique avec des antagonistes glp-1
EP3341404A4 (fr) Nouveaux analogues d'insuline et leur utilisation
EP3603660A4 (fr) Nouvelle application pour facteur de croissance des fibroblastes humains mutants à action prolongée
EP3285793A4 (fr) Mutants du facteur de croissance des fibroblastes (fgf) 1 et leurs procédés d'utilisation pour réduire le glucose sanguin
EP3363450A4 (fr) Composition de médecine traditionnelle chinoise pour le traitement du psoriasis
EP3515525A4 (fr) Canule cardiaque
HK1244216A1 (zh) 治療2型糖尿病患者
EP3383370A4 (fr) Formulation d'anesthésique local sur une durée prolongée
EP3049100A4 (fr) Facteurs de croissance des fibroblastes modifiés pour le traitement de troubles oculaires
EP3340951A4 (fr) Bandage chirurgical doté d'éléments de stabilisation
EP3190887A4 (fr) Procédés de traitement et de prévention de maladies, de troubles et d'affections oculaires avec de la mélanine et des analogues, des précurseurs, et des dérivés de mélanine
IL254500A0 (en) Treatment of patients with type 2 diabetes
GB201403996D0 (en) Traditional chinese medicine composition for the treatment of diabetes
GB201707207D0 (en) Treatment of type 1 diabetes
EP3524231A4 (fr) Préparation stabilisée de variant d'interféron bêta
EP3487876A4 (fr) Analogues de l'insuline

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190222

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/18 20060101AFI20190218BHEP

Ipc: A61P 3/08 20060101ALI20190218BHEP

Ipc: C07K 19/00 20060101ALI20190218BHEP

Ipc: C07K 14/50 20060101ALI20190218BHEP

Ipc: A61P 3/04 20060101ALI20190218BHEP

17Q First examination report despatched

Effective date: 20200108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603